JDTic is a powerful antagonist of kappa-opioid receptors (KOR), effectively inhibiting the antinociceptive effects induced by the κ-agonist U50, 488.

JDTic administered intraperitoneally (i.p.) at a dose of 10 mg/kg effectively reduces alcohol self-administration, inhibits cue-induced alcohol seeking, and selectively antagonizes the effects of a kappa-opioid receptor (KOR) agonist 2 hours after treatment. At a higher dose (30 mg/kg) given intragastrically (i.g.), JDTic significantly prevents U50,488-induced diuresis in rats. When administered subcutaneously (s.c.) in doses ranging from 2.5 to 16 mg/kg, JDTic dose-dependently inhibits the antinociceptive effects of nicotine in the tail-flick test without affecting outcomes in the hot-plate test or altering body temperature in nicotine-injected mice. Additionally, a 3 mg/kg i.p. dose of JDTic effectively ameliorates anxiety-like behavior in a rat model of hangover anxiety.